Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00124007
First received: July 22, 2005
Last updated: July 7, 2014
Last verified: July 2014

July 22, 2005
July 7, 2014
November 2005
Not Provided
  • Local reactogenicity signs and symptoms
  • systemic reactogenicity signs and symptoms
  • laboratory measures of safety
  • adverse and serious adverse experiences
Same as current
Complete list of historical versions of study NCT00124007 on ClinicalTrials.gov Archive Site
  • Proportion of volunteers who have HIV-1 specific T-cell responses quantified by intracellular cytokine staining (ICS; both CD4+ and CD8+) and ELISPOT and magnitude of the responses
  • proportion of volunteers with HIV-1 specific antibodies and magnitude of the response
  • proportion of volunteers with increase in antibodies to rAd5
  • impact of pre-existing immunity to rAd5 on immunogenicity
  • proportion of volunteers who test "false positive" on standard HIV testing algorithm.
Same as current
Not Provided
Not Provided
 
Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults
A Phase I, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine Followed by Recombinant, Multiclade HIV-1 Adenoviral Vector Vaccine or the Multiclade HIV-1 Adenoviral Vector Vaccine Alone in Healthy Adult Volunteers Not Infected With HIV

The purpose of this study is to determine the safety of and immune response to an investigational HIV vaccine, VRC-HIVADV014-00-VP, with or without a second investigational HIV vaccine, VRC-HIVDNA016-00-VP, in HIV uninfected adults.

The worldwide HIV/AIDS epidemic may only be controlled through development of a safe and effective vaccine that will prevent HIV infection. This study will evaluate the safety and immunogenicity of an experimental adenovirus-vectored multiclade HIV vaccine, VRC-HIVADV014-00-VP, followed with either a similarly structured DNA plasmid HIV vaccine, VRC-HIVDNA016-00-VP, or a placebo. The DNA plasmids in both vaccines code for proteins from HIV subtypes A, B, and C, which together represent 90% of new HIV infections in the world. HIV uninfected volunteers will be recruited in Kenya and Rwanda.

Volunteers will participate in this study for 1 year. Participants will be randomly assigned to one of four groups:

  • Group A participants will receive a low dose of the adenovirus-vectored vaccine or placebo at study entry.
  • Group B participants will receive a higher dose of the adenovirus-vectored vaccine or placebo at study entry.
  • Group C participants will receive the DNA plasmid vaccine or placebo at study entry and Months 1 and 2. They will receive either a low dose of the adenovirus-vectored vaccine or placebo at Month 6.
  • Group D participants will receive the DNA plasmid vaccine or placebo at study entry and Months 1 and 2. They will receive either a higher dose of the adenovirus-vectored vaccine or placebo at Month 6.

All participants will undergo vital signs measurements before and after receiving each vaccination.

Participants in Groups A and B will have 9 study visits over 12 months. A physical exam, adverse events reporting, and medical and medication history will occur at each visit. HIV testing and counseling and blood and urine collection will occur at selected visits.

Participants in Groups C and D will have 17 study visits over 12 months. A physical exam, adverse events reporting, and medical and medication history will occur at each visit. HIV testing and counseling and blood and urine collection will occur at selected visits.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Diagnostic
HIV Infections
  • Biological: VRC-HIVADV014-00-VP
  • Biological: VRC-HIVDNA016-00-VP
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
114
April 2007
Not Provided

Inclusion Criteria:

  • Willing to follow all the requirements of the study and available for follow-up for the duration of the study
  • Have understanding of the study and provide written informed consent
  • Willing to undergo HIV testing and counseling and willing to receive HIV test results
  • Willing to use acceptable forms of contraception

Exclusion Criteria:

  • HIV infected
  • Hepatitis B virus infected
  • Hepatitis C virus infected
  • Active or untreated syphilis
  • Participated in high-risk behavior for HIV infection within 6 months prior to study entry. More information on this criterion can be found in the protocol.
  • Any clinically significant abnormality in history or upon examination (e.g., immunodeficiency or autoimmune disease; use of systemic corticosteroids, immunosuppressive, antiviral, anticancer, or other medications considered significant by the investigator) within 6 months prior to study entry
  • Any clinically significant acute or chronic medical condition that, in the opinion of the investigator, would make the volunteer unsuitable for the study
  • Live attenuated vaccines within 30 days prior to study entry OR plan to receive a live attenuated vaccine within 60 days after vaccination in this study
  • Subunit or killed vaccines within 14 days prior to study entry OR plan to receive a subunit or killed vaccine within 14 days after vaccination in this study
  • Blood transfusion or blood products within 120 days prior to study entry
  • Immunoglobulin within 60 days prior to study entry
  • Participation in another investigational product clinical trial in the 3 months prior to study entry OR expected to participate in another investigational trial during this study
  • Any other investigational HIV vaccine at any time
  • History of severe local or systemic reactogenicity to vaccines or history of severe allergic reactions
  • Major psychiatric illness, including any history of schizophrenia or severe psychosis, bipolar disorder requiring therapy, or suicide attempt or suicidal thoughts within the 3 years prior to study entry
  • Uncontrolled hypertension
  • Pregnant, breastfeeding, or plan to become pregnant
Both
18 Years to 50 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Kenya,   Rwanda
 
NCT00124007
IAVI V001, 10380
Not Provided
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
Not Provided
Principal Investigator: Job Bwayo, MD, PhD Kenya AIDS Vaccine Initiative, University of Nairobi
Principal Investigator: Etienne Karita, MD Project San Francisco
National Institute of Allergy and Infectious Diseases (NIAID)
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP